Alcon Inc Dossier
Qualitative Analysis
Business overview
Alcon Inc. (SIX/NYSE:ALC) is the global leader in eye care, with a heritage spanning over 75 years. The company researches, develops, manufactures, distributes, and sells a comprehensive suite of ophthalmic products across two primary business segments: Surgical and Vision Care. The Surgical segment (accounting for approximately 55.7% of net sales) focuses on ophthalmic surgical products, equipment, consumables, and implantables (such as intraocular lenses) used to treat cataracts, retinal diseases, glaucoma, and refractive errors. The Vision Care segment (accounting for approximately 44.3% of net sales) comprises contact lenses and ocular health products, including dry-eye drops and ophthalmic ointments. Alcon operates 17 production sites globally and serves patients in over 140 countries.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
An enterprise-wide operational improvement initiative designed to streamline processes and optimize the global supply chain.
Expected impact: Targeting roughly $100 million in run-rate savings, with approximately $50 million expected to benefit the fiscal year 2026.
Alcon's long-term environmental strategy focused on energy efficiency, greenhouse gas reduction, operational waste reduction, and water stewardship across its global manufacturing and distribution footprint.
Expected impact: As of the 2025 reporting period, Alcon has reduced Scope 1 and Scope 2 emissions by 35% and successfully diverted 99% of non-hazardous waste from landfills.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Brings Alcon the Valeda Photobiomodulation (PBM) device, the only non-invasive technology providing visual improvement in dry age-related macular degeneration (AMD) patients. The transaction expands Alcon's footprint from the operating room into the retina clinic and dry AMD space.
Financial impact: Began generating revenue in late 2025, with broader top-line acceleration expected as international regulatory approvals are secured in 2026.
Acquisition of the manufacturer of the Implantable Collamer Lens (ICL), including the EVO family of lenses for moderate to high myopia correction. The transaction is highly complementary to Alcon's existing laser vision correction business and positions the company to offer a full spectrum of refractive treatments.
Financial impact: The transaction values STAAR at approximately $1.5 billion in equity value ($28 per share in cash) and is expected to be accretive to Alcon's earnings in the second year post-close.
Strategic Partnerships
High. The partnership focuses on co-developing adjustable presbyopia-correcting intraocular lenses (PCIOLs), combining RxSight's postoperative light-adjustable technology with Alcon's proprietary PCIOL optical designs to allow surgeons to customize patient vision after cataract surgery.
Terms: RxSight receives an upfront payment of $60 million to initiate development and is eligible to earn up to an additional $140 million based on the achievement of specified development and regulatory milestones.
Medium. Launch of the Aravind Alcon Global Centre of Excellence (CoE) for Vitreoretinal Surgery Training in Coimbatore, India. This marks the second phase of their partnership (following the 2024 Cataract CoE) to address global shortages in trained retina specialists across underserved regions.
Terms: Combines hands-on surgical training with scalable virtual education, featuring a state-of-the-art wet laboratory to train approximately 60 participants annually.